Prospective randomized controlled trial study of liver function tests in unstable angina risk prediction

Cardiovascular diseases continue to be the leading cause of morbidity and mortality in developed nations. Elevated levels of liver function have recently been implicated as possible risk factors for cardiovascular disease in the adult population. This study aims to assess the correlation between hepatic function tests and both cardiac troponin I (cTn I) and high-sensitivity C-reactive protein (hs-CRP) in adult males with unstable angina. Additionally, to explore the potential of these biomarkers as predictive tools. The project was conducted at AL-Ramadi Teaching Hospital, Iraq, from October 2023 to January 2024. The study included 90 male adult participants, 60 persons in a healthy control group, and 30 patients with unstable angina. Socio-demographic and biochemical variables were collected using a systematic questionnaire and standardized measurement procedures. The average values for body mass index, systolic blood pressure, diastolic blood pressure, triglycerides, total cholesterol, low-density lipoprotein cholesterol, alkaline phosphatase, aspartate aminotransferase, gamma-glutamyl transferase, cTn I, and hs-CRP were significantly higher (P<0.05) in unstable angina patients compared to the control group. Furthermore, a significant correlation between bilirubin, GGT, and AST levels and both cTnI and hs-CRP levels were detected in unstable angina patients. In conclusion, our data indicate that bilirubin, GGT, and AST possess the best predictive value for the risk of unstable angina in comparison to other liver tests. As a result, continued monitoring of these biomarkers in patients suffering from liver function disorders will not only identify early signs of unstable angina but will also improve the prevention and treatment of the disease.